<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459846</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Limited Short-Term Evolution of SARS-CoV-2 RNA-Dependent RNA Polymerase under Remdesivir Exposure in Upper Respiratory Compartments.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1511</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101511</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The extent of the SARS-CoV-2 short-term evolution under Remdesivir (RDV) exposure and whether it varies across different upper respiratory compartments are not fully understood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients hospitalized for COVID-19, with or without RDV therapy, were enrolled and completed up to three visits, in which they provided specimens from four respiratory compartments. Near full-length genome SARS-CoV-2 sequences were obtained from viral RNA, standard lineage and variant assignments were performed, and viral mutations in the RNA-dependent RNA polymerase (RdRp) region-the RDV target gene-were detected and compared between participants with and without RDV, across the four compartments, within participants across visits, and versus a larger sequence dataset. The statistical analysis used a generalized linear mixed-effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 139 sequences were obtained from 37 out of the 44 (84%) enrolled participants. The genotyping success varied across respiratory compartments, which ranged from 42% with oropharyngeal specimens to 67% with nasopharyngeal specimens and showed improvement with higher viral loads. No RdRp mutations known to be associated with RDV resistance were identified, and for 34 detected mutations at 32 amino acid positions that are not known as RDV-associated, there was no evidence of any associations with the RDV exposure, respiratory compartment, or time. At least 1 of these 34 mutations were detected in all participants, and some differed from the larger sequence dataset.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study highlighted the SARS-CoV-2 short-term genomic stability within hosts and across upper respiratory compartments, which suggests a lack of evolution of RDV resistance over time. This contributes to our understanding of SARS-CoV-2 genomic dynamics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novitsky</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckwith</LastName><ForeName>Curt G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carpenter-Azevedo</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>State Health Laboratories, Rhode Island Department of Health, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jimin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1584-8947</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of Connecticut, Farmington, CT 06030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hague</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sam</LastName><ForeName>Soya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steingrimsson</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huard</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>State Health Laboratories, Rhode Island Department of Health, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lethbridge</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rhode Island Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahu</LastName><ForeName>Sujata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapoza</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazerman</LastName><ForeName>Lauri</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hipolito</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rhode Island Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Rhode Island Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carnevale</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rhode Island Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guang</LastName><ForeName>August</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Computational Biology Core, Center for Computation and Visualization, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillani</LastName><ForeName>Fizza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rhode Island Hospital, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caliendo</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantor</LastName><ForeName>Rami</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3659-1108</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CO-US-540-6139</GrantID><Agency>Gilead Sciences (United States)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D000086422">Coronavirus RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="Y">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="Y">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086422" MajorTopicYN="N">Coronavirus RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009960" MajorTopicYN="N">Oropharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RdRp</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">drug resistance</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">respiratory compartments</Keyword></KeywordList><CoiStatement>A.M.C. served as a member of the following Scientific Advisory Boards: Danaher/Cepheid/Beckman Coulter, First Light, Visby, and Lab Simply. All other authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459846</ArticleId><ArticleId IdType="pmc">PMC11512361</ArticleId><ArticleId IdType="doi">10.3390/v16101511</ArticleId><ArticleId IdType="pii">v16101511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  WHO Coronovirus (COVID-19) Dashboard. United States of America Situation.  [(accessed on 14 June 2024)].  Available online:  https://covid19.who.int/region/amro/country/us.</Citation></Reference><Reference><Citation>WHO  WHO Coronovirus (COVID-19) Dashboard. Global Situation.  [(accessed on 14 June 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>CDC CDC Public Health Science Agenda for COVID-19.  [(accessed on 8 June 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/science/science-agenda-covid19.html.</Citation></Reference><Reference><Citation>Snijder E.J., Decroly E., Ziebuhr J. The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. Adv. Virus Res. 2016;96:59–126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112286</ArticleId><ArticleId IdType="pubmed">27712628</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon A., Le N.T., Selisko B., Eydoux C., Alvarez K., Guillemot J.C., Decroly E., Peersen O., Ferron F., Canard B. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antivir. Res. 2020;178:104793. doi: 10.1016/j.antiviral.2020.104793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104793</ArticleId><ArticleId IdType="pmc">PMC7151495</ArticleId><ArticleId IdType="pubmed">32283108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F., Zhao W., Gao M., et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499–1504. doi: 10.1126/science.abc1560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1560</ArticleId><ArticleId IdType="pmc">PMC7199908</ArticleId><ArticleId IdType="pubmed">32358203</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L., et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779–782. doi: 10.1126/science.abb7498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7498</ArticleId><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Subissi L., Imbert I., Ferron F., Collet A., Coutard B., Decroly E., Canard B. SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets. Antivir. Res. 2014;101:122–130. doi: 10.1016/j.antiviral.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.11.006</ArticleId><ArticleId IdType="pmc">PMC7113864</ArticleId><ArticleId IdType="pubmed">24269475</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir. Chem. Chemother. 2018;26:2040206618764483. doi: 10.1177/2040206618764483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206618764483</ArticleId><ArticleId IdType="pmc">PMC5890544</ArticleId><ArticleId IdType="pubmed">29562753</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Franchini M., Maggi F., Shoham S. COVID-19 therapeutics. Clin. Microbiol. Rev. 2024;37:e0011923. doi: 10.1128/cmr.00119-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.00119-23</ArticleId><ArticleId IdType="pmc">PMC11237566</ArticleId><ArticleId IdType="pubmed">38771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Singh A., Singh R., Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab. Syndr. 2020;14:641–648. doi: 10.1016/j.dsx.2020.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.05.018</ArticleId><ArticleId IdType="pmc">PMC7214279</ArticleId><ArticleId IdType="pubmed">32428865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb Y.N. Remdesivir: First Approval. Drugs. 2020;80:1355–1363. doi: 10.1007/s40265-020-01378-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01378-w</ArticleId><ArticleId IdType="pmc">PMC7459246</ArticleId><ArticleId IdType="pubmed">32870481</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health.  [(accessed on 8 June 2024)]; Available online:  https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.</Citation></Reference><Reference><Citation>NIH  COVID-19 Treatment Guidlines. Remdesivir.  [(accessed on 8 June 2024)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/remdesivir/</Citation></Reference><Reference><Citation>Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M.L., Lescure F.X., et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 2020;382:2327–2336. doi: 10.1056/NEJMoa2007016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007016</ArticleId><ArticleId IdType="pmc">PMC7169476</ArticleId><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner C.D., Gottlieb R.L., Criner G.J., Arribas Lopez J.R., Cattelan A.M., Soriano Viladomiu A., Ogbuagu O., Malhotra P., Mullane K.M., Castagna A., et al. Effect of Remdesivir vs. Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:1048–1057. doi: 10.1001/jama.2020.16349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman J.D., Lye D.C.B., Hui D.S., Marks K.M., Bruno R., Montejano R., Spinner C.D., Galli M., Ahn M.Y., Nahass R.G., et al. Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. N. Engl. J. Med. 2020;383:1827–1837. doi: 10.1056/NEJMoa2015301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015301</ArticleId><ArticleId IdType="pmc">PMC7377062</ArticleId><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Olender S.A., Perez K.K., Go A.S., Balani B., Price-Haywood E.G., Shah N.S., Wang S., Walunas T.L., Swaminathan S., Slim J., et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. Clin. Infect. Dis. 2020;73:e4166–e4174. doi: 10.1093/cid/ciaa1041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1041</ArticleId><ArticleId IdType="pmc">PMC7454434</ArticleId><ArticleId IdType="pubmed">32706859</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19-Preliminary Report. N. Engl. J. Med. 2020;383:1813–1836. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Frediansyah A., Nainu F., Dhama K., Mudatsir M., Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin. Epidemiol. Glob. Health. 2020;9:123–127. doi: 10.1016/j.cegh.2020.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2020.07.011</ArticleId><ArticleId IdType="pmc">PMC7410793</ArticleId><ArticleId IdType="pubmed">32838064</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Wang X., Cao D., Sun R., Li C., Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov. Ther. 2020;14:73–76. doi: 10.5582/ddt.2020.01015.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2020.01015</ArticleId><ArticleId IdType="pubmed">32378648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Ryan P., Nielsen B.U., Brown M., et al. Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients. N. Engl. J. Med. 2022;386:305–315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens L.J., Pruijssers A.J., Lee H.W., Gordon C.J., Tchesnokov E.P., Gribble J., George A.S., Hughes T.M., Lu X., Li J., et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci. Transl. Med. 2022;14:eabo0718. doi: 10.1126/scitranslmed.abo0718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo0718</ArticleId><ArticleId IdType="pmc">PMC9097878</ArticleId><ArticleId IdType="pubmed">35482820</ArticleId></ArticleIdList></Reference><Reference><Citation>Szemiel A.M., Merits A., Orton R.J., MacLean O.A., Pinto R.M., Wickenhagen A., Lieber G., Turnbull M.L., Wang S., Furnon W., et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 2021;17:e1009929. doi: 10.1371/journal.ppat.1009929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009929</ArticleId><ArticleId IdType="pmc">PMC8496873</ArticleId><ArticleId IdType="pubmed">34534263</ArticleId></ArticleIdList></Reference><Reference><Citation>Checkmahomed L., Carbonneau J., Du Pont V., Riola N.C., Perry J.K., Li J., Pare B., Simpson S.M., Smith M.A., Porter D.P., et al. In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance. Antimicrob. Agents Chemother. 2022;66:e0019822. doi: 10.1128/aac.00198-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00198-22</ArticleId><ArticleId IdType="pmc">PMC9295571</ArticleId><ArticleId IdType="pubmed">35708323</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X., Smith E.C., Case J.B., Feng J.Y., Jordan R., et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9:e00221-18. doi: 10.1128/mBio.00221-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00221-18</ArticleId><ArticleId IdType="pmc">PMC5844999</ArticleId><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Maggi F., McConnell S., Casadevall A. Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antivir. Res. 2022;198:105247. doi: 10.1016/j.antiviral.2022.105247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105247</ArticleId><ArticleId IdType="pmc">PMC8755559</ArticleId><ArticleId IdType="pubmed">35033572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A., Roloff T., Stange M., Sogaard K.K., Asllanaj E., Tauriello G., Alexander L.T., Schweitzer M., Leuzinger K., Gensch A., et al. Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. Microorganisms. 2021;9:1094. doi: 10.3390/microorganisms9051094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9051094</ArticleId><ArticleId IdType="pmc">PMC8160703</ArticleId><ArticleId IdType="pubmed">34069681</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinot M., Jary A., Fafi-Kremer S., Leducq V., Delagreverie H., Garnier M., Pacanowski J., Mekinian A., Pirenne F., Tiberghien P., et al. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clin. Infect. Dis. 2021;73:e1762–e1765. doi: 10.1093/cid/ciaa1474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1474</ArticleId><ArticleId IdType="pmc">PMC7543308</ArticleId><ArticleId IdType="pubmed">32986807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S., Klein J., Robertson A.J., Pena-Hernandez M.A., Lin M.J., Roychoudhury P., Lu P., Fournier J., Ferguson D., Mohamed Bakhash S.A.K., et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report. Nat. Commun. 2022;13:1547. doi: 10.1038/s41467-022-29104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29104-y</ArticleId><ArticleId IdType="pmc">PMC8930970</ArticleId><ArticleId IdType="pubmed">35301314</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Multani A., Garrigues J.M., Oh M.S., Hemarajata P., Burleson T., Green N.M., Oliai C., Gaynor P.T., Beaird O.E., et al. Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation. Microorganisms. 2023;11:2096. doi: 10.3390/microorganisms11082096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11082096</ArticleId><ArticleId IdType="pmc">PMC10460003</ArticleId><ArticleId IdType="pubmed">37630656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan J.I., Duerr R., Dimartino D., Marier C., Hochman S.E., Mehta S., Wang G., Heguy A. Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019. Clin. Infect. Dis. 2023;76:342–345. doi: 10.1093/cid/ciac769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac769</ArticleId><ArticleId IdType="pmc">PMC9619446</ArticleId><ArticleId IdType="pubmed">36156117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi A.S., Zadheidar S., Sadeghi K., Nejati A., Salimi V., Hajiabdolbaghi M., Mokhtari-Azad T., Yavarian J. SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment. J. Med. Virol. 2023;95:e28877. doi: 10.1002/jmv.28877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28877</ArticleId><ArticleId IdType="pubmed">37341553</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyer A., Gunther T., Robitaille A., Lutgehetmann M., Addo M.M., Jarczak D., Kluge S., Aepfelbacher M., Schulze Zur Wiesch J., Fischer N., et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med. 2022;3:100735. doi: 10.1016/j.xcrm.2022.100735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100735</ArticleId><ArticleId IdType="pmc">PMC9378267</ArticleId><ArticleId IdType="pubmed">36075217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirmalarajah K., Yim W., Aftanas P., Li A.X., Shigayeva A., Yip L., Zhong Z., McGeer A.J., Maguire F., Mubareka S., et al. Use of whole genome sequencing to identify low-frequency mutations in SARS-CoV-2 patients treated with remdesivir. Influenza Other Respir. Viruses. 2023;17:e13179. doi: 10.1111/irv.13179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13179</ArticleId><ArticleId IdType="pmc">PMC10522481</ArticleId><ArticleId IdType="pubmed">37752062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedskog C., Rodriguez L., Roychoudhury P., Huang M.L., Jerome K.R., Hao L., Ireton R.C., Li J., Perry J.K., Han D., et al. Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1) J. Infect. Dis. 2023;228:1263–1273. doi: 10.1093/infdis/jiad270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad270</ArticleId><ArticleId IdType="pmc">PMC10629708</ArticleId><ArticleId IdType="pubmed">37466213</ArticleId></ArticleIdList></Reference><Reference><Citation>DNA Pipelines R&amp;D. Farr B., Rajan D., Dawson E., Shirley L., Quail M., Park N., Redshaw N., Bronner I.F., Aigrain L., et al.  COVID-19 ARTIC v3 Illumina Library Construction and Sequencing Protocol V.5.  [(accessed on 5 February 2021)].  Available online:  https://www.protocols.io/view/covid-19-artic-v3-illumina-library-construction-an-j8nlke665l5r/v5.</Citation></Reference><Reference><Citation>Centre for Genomic Pathogen Surveillance Pangolin: Phylogenetic Assignment of Named Global Outbreak LINeages.  [(accessed on 6 June 2023)].  Available online:  https://github.com/cov-lineages/pangolin.</Citation></Reference><Reference><Citation>Nextstrain Project Nextclade: Clade Assignment, Mutation Calling, and Sequence Quality Checks.  [(accessed on 6 June 2023)].  Available online:  https://clades.nextstrain.org/</Citation></Reference><Reference><Citation>Aksamentov I., Roemer C., Hodcroft E.B., Neher R.A. Nextclade: Clade assignment, mutation calling and quality control for viral genomes. J. Open Source Softw. 2021;6:3773. doi: 10.21105/joss.03773.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.03773</ArticleId></ArticleIdList></Reference><Reference><Citation>A Stanford HIVDB Team Website Stanford University Coronovirus Aniviral &amp; Resistance Database.  [(accessed on 6 June 2023)].  Available online:  https://covdb.stanford.edu/drms/rdrp/</Citation></Reference><Reference><Citation>Hirotsu Y., Kobayashi H., Kakizaki Y., Saito A., Tsutsui T., Kawaguchi M., Shimamura S., Hata K., Hanawa S., Toyama J., et al. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med. 2023;4:813–824.e4. doi: 10.1016/j.medj.2023.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.08.001</ArticleId><ArticleId IdType="pubmed">37683636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi: 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>GISAID  Global Initiative on Sharing All Influenza Data (GISAID) Repository.  [(accessed on 24 May 2024)].  Available online:  https://www.epicov.org.</Citation></Reference><Reference><Citation>Carstensen B., Plummer M., Laara E., Hills M. Epi: Statistical Analysis in Epidemiology.  [(accessed on 10 June 2024)].  Available online:  https://cran.r-project.org/web/packages/Epi/index.html.</Citation></Reference><Reference><Citation>R Core Team  The R Project for Statistical Computing.  [(accessed on 19 May 2023)].  Available online:  http://www.R-project.org/</Citation></Reference><Reference><Citation>Troseid M., Hentzien M., Ader F., Cardoso S.W., Arribas J.R., Molina J.M., Mueller N., Hites M., Bonnet F., Manuel O., et al. Combine, Immunocompromised patients have been neglected in COVID-19 trials: A call for action. Clin. Microbiol. Infect. 2022;28:1182–1183. doi: 10.1016/j.cmi.2022.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.05.005</ArticleId><ArticleId IdType="pmc">PMC9130310</ArticleId><ArticleId IdType="pubmed">35623577</ArticleId></ArticleIdList></Reference><Reference><Citation>Majchrzak M., Madej L., Lysek-Gladysinska M., Zarebska-Michaluk D., Zegadlo K., Dziuba A., Nogal-Nowak K., Kondziolka W., Sufin I., Myszona-Tarnowska M., et al. The RdRp genotyping of SARS-CoV-2 isolated from patients with different clinical spectrum of COVID-19. BMC Infect. Dis. 2024;24:281. doi: 10.1186/s12879-024-09146-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09146-x</ArticleId><ArticleId IdType="pmc">PMC10913261</ArticleId><ArticleId IdType="pubmed">38439047</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya R., Mishra P., Swaminathan A., Ravi V., Saifi S., Kanakan A., Mehta P., Devi P., Praveen S., Budhiraja S., et al. SARS-CoV-2 Mutations and COVID-19 Clinical Outcome: Mutation Global Frequency Dynamics and Structural Modulation Hold the Key. Front. Cell Infect. Microbiol. 2022;12:868414. doi: 10.3389/fcimb.2022.868414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.868414</ArticleId><ArticleId IdType="pmc">PMC8978958</ArticleId><ArticleId IdType="pubmed">35386683</ArticleId></ArticleIdList></Reference><Reference><Citation>Saifi S., Ravi V., Sharma S., Swaminathan A., Chauhan N.S., Pandey R. SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength? Genomics. 2022;114:110466. doi: 10.1016/j.ygeno.2022.110466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2022.110466</ArticleId><ArticleId IdType="pmc">PMC9419439</ArticleId><ArticleId IdType="pubmed">36041637</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala E., Shah I.S., Manissero D., Juanola-Falgarona M., Quirke A.M., Rao S.N. Systematic Review on the Correlation Between SARS-CoV-2 Real-Time PCR Cycle Threshold Values and Epidemiological Trends. Infect. Dis. Ther. 2023;12:749–775. doi: 10.1007/s40121-023-00772-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-023-00772-7</ArticleId><ArticleId IdType="pmc">PMC9945817</ArticleId><ArticleId IdType="pubmed">36811776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagman K., Hedenstierna M., Widaeus J., Arvidsson E., Hammas B., Grillner L., Jakobsson J., Gille-Johnson P., Ursing J. Correlation of SARS-CoV-2 Nasopharyngeal CT Values With Viremia and Mortality in Adults Hospitalized With COVID-19. Open Forum Infect. Dis. 2022;9:ofac463. doi: 10.1093/ofid/ofac463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac463</ArticleId><ArticleId IdType="pmc">PMC9518228</ArticleId><ArticleId IdType="pubmed">36185351</ArticleId></ArticleIdList></Reference><Reference><Citation>Juanola-Falgarona M., Penarrubia L., Jimenez-Guzman S., Porco R., Congost-Teixidor C., Varo-Velazquez M., Rao S.N., Pueyo G., Manissero D., Pareja J. Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx(R) Respiratory SARS-CoV-2 Panel. Int. J. Infect. Dis. 2022;122:930–935. doi: 10.1016/j.ijid.2022.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.07.022</ArticleId><ArticleId IdType="pmc">PMC9273520</ArticleId><ArticleId IdType="pubmed">35840097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>